Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: A national population-based cohort study

Journal of Clinical Oncology

Volumn 33, Issue 31, 2015, Pages 3641-3649

  Østgård, Lene Sofie Granfeldt ^a   Medeiros, Bruno C ^f   Sengeløv, Henrik ^b   Nørgaard, Mette ^a   Andersen, Mette Klarskov ^b   Dufva, Ingehøgh ^c   Friis, Lone Smidstrup ^b   Kjeldsen, Eigil ^a   Marcher, Claus Werenberg ^d   Preiss, Birgitte ^d   Severinsen, Marianne ^e   Nørgaard, Jan Maxwell ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; IDARUBICIN; MITOXANTRONE; ANTINEOPLASTIC AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CYTOGENETICS; DENMARK; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; INTENSIVE CARE; KARYOTYPE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; SECOND CANCER; SECONDARY ACUTE MYELOID LEUKEMIA; THERAPY RELATED ACUTE MYELOID LEUKEMIA; TREATMENT RESPONSE; CHEMICALLY INDUCED; COMPLICATION; HEMATOLOGIC DISEASES; KAPLAN MEIER METHOD; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; REGISTER; REGRESSION ANALYSIS; REMISSION; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DENMARK; FEMALE; HEMATOLOGIC DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; REGISTRIES; REGRESSION ANALYSIS; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84947258738     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.0890     Document Type: Article

References (39)

1. Swerdlow SH, Campo E, Harris NL: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Geneva, Switzerland, WHO, 2008
2. Kayser S, Döhner K, Krauter J, et al: The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117:2137-2145, 2011
3. Schoch C, Kern W, Schnittger S, et al: Karyo-type is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): An analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 18:120-125, 2004
4. Miesner M, Haferlach C, Bacher U, et al: Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: A comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC). Blood 116:2742-2751, 2010
5. Hulegårdh E, Nilsson C, Lazarevic V, et al: Characterization and prognostic features of secondary acute myeloid leukemia (AML) in a population-based setting: A report from the Swedish Acute Leukemia Registry. Am J Hematol 90:208-214, 2015
6. Smith SM, Le Beau MM, Huo D, et al: Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 102:43-52, 2003
7. Koh Y, Kim I, Bae JY, et al: Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8. Jpn J Clin Oncol 40:1037-1045, 2010
8. Larson RA: Etiology and management of therapy-related myeloid leukemia. Hematology Am Soc Hematol Educ Program 2007:453-459, 2007
9. Ramsingh G, Young A, Shen D, et al: The role of early TP53 mutations on the evolution of therapy-related AML. Blood 122:5-5, 2013 (abstr)
10. Christiansen DH, Andersen MK, Pedersen-Bjergaard J: Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 19:1405-1413, 2001
11. Morton LM, Dores GM, Tucker MA, et al: Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood 121:2996-3004, 2013
12. Larson RA: Cytogenetics, not just previous therapy, determines the course of therapy-related myeloid neoplasms. J Clin Oncol 30:2300-2302, 2012
13. Østgård LS, Nørgaard JM, Severinsen MT, et al: Data quality in the Danish National Acute Leukemia Registry: A hematological data resource. Clin Epidemiol 5:335-344, 2013
14. Storm HH, Michelsen EV, Clemmensen IH, et al: The Danish Cancer Registry: History, content, quality and use. Dan Med Bull 44:535-539, 1997
15. Andersen TF, Madsen M, Jørgensen J, et al: The Danish National Hospital Register: A valuable source of data for modern health sciences. Dan Med Bull 46:263-268, 1999
16. Grimwade D, Hills RK, Moorman AV, et al: Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council Trials. Blood 116:354-365, 2010
17. Østgård LS, Nørgaard JM, Sengeløv H, et al: Comorbidity and performance status in acute myeloid leukemia patients: A nation-wide population-based cohort study. Leukemia 29:548-555, 2015
18. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003
19. Greenland S: Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol 160:301-305, 2004
20. Klein JP, Logan B, Harhoff M, et al: Analyzing survival curves at a fixed point in time. Stat Med 26:4505-4519, 2007
21. Andersen PK, Hansen MG, Klein JP: Regression analysis of restricted mean survival time based on pseudo-observations. Lifetime Data Anal 10:335-350, 2004
22. Parner E, Andersen P: Regression analysis of censored data using pseudo-observations. Stata J 10:408-422, 2010
23. Thygesen SK, Christiansen CF, Christensen S, et al: The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish national registry of patients. BMC Med Res Methodol 11:83, 2011
24. Bacher U, Haferlach T: The benefit of population-based studies for older patients with acute myeloid leukemia. Haematologica 97:1781-1782, 2012
25. Rothman KJ, Greenland S, Lash TL: Modern Epidemiology (ed 3). Philadelphia, PA, Wolters Kluwer, 2008
26. Craig BM, Rollison DE, List AF, et al: Underreporting of myeloid malignancies by United States cancer registries. Cancer Epidemiol Biomarkers Prev 21:474-481, 2012
27. Mauritzson N, Albin M, Rylander L, et al: Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 16: 2366-2378, 2002
28. Walter MJ, Shen D, Ding L, et al: Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 366:1090-1098, 2012
29. Mendler JH, Maharry K, Radmacher MD, et al: RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures. J Clin Oncol 30:3109-3118, 2012
30. Krauth MT, Alpermann T, Bacher U, et al: WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups. Leukemia 29:660-667, 2015
31. Bacher U, Haferlach T, Kern W, et al: A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 92:744-752, 2007
32. Medeiros BC, Othus M, Fang M, et al: Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia. Haematologica 100:331-335, 2015
33. Bochtler T, Stölzel F, Heilig CE, et al: Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. J Clin Oncol 31:3898-3905, 2013
34. Pedersen-Bjergaard J, Andersen MK, Andersen MT, et al: Genetics of therapy-related myelodys-plasia and acute myeloid leukemia. Leukemia 22: 240-248, 2008
35. Litzow MR, Tarima S, Pérez WS, et al: Allogeneic transplantation for therapy-related myelodys-plastic syndrome and acute myeloid leukemia. Blood 115:1850-1857, 2010
36. Taskesen E, Bullinger L, Corbacioglu A, et al: Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: Further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 117:2469-2475, 2011
37. Patel JP, Gönen M, Figueroa ME, et al: Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366:1079-1089, 2012
38. Paschka P, Schlenk RF, Gaidzik VI, et al: IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28:3636-3643, 2010
39. Metzeler KH, Becker H, Maharry K, et al: ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN favorable genetic category. Blood 118:6920-6929, 2011